Compare IART & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | EYPT |
|---|---|---|
| Founded | 1989 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1996 | 2005 |
| Metric | IART | EYPT |
|---|---|---|
| Price | $14.92 | $13.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $14.33 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.1M | 724.3K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $3.40 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.70 | $5.57 |
| 52 Week High | $16.42 | $19.11 |
| Indicator | IART | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 50.55 |
| Support Level | $12.64 | $12.66 |
| Resistance Level | $16.35 | $14.73 |
| Average True Range (ATR) | 0.90 | 0.74 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 84.02 | 58.84 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.